Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study

Abstract

The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy.

Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study

“…However, 70% of the patients participating in this survey were women and the mean age was 78.0 years, which is consistent with the epidemiology of the disease [18,19,20]. Furthermore, the mean number of injections (4.7 during the last year) and follow-up visits (n = 8) reported in the EQUADE study were also consistent with two previously conducted real-life studies on exudative AMD patients [6,21]. Considering VA, 75.4% of the patients included in this study were able to self-report VA for at least one eye, which is a relatively high percentage.…”

Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice

“…During the 12-month period preceding the switch, eyes received an average of 6.7±2.7 IVR, and they received an average of 2.1±0.8 IVR 3 months before the switch. After switch, eyes were treated with a mean 2.3 intravitreal injections of aflibercept (IVA; range, [1][2][3][4][5]. During the switch period, 14 eyes (29.7 %) received three successive IVA, and 23 (48.9 %) received three to five IVA.…”

“…Although ranibizumab has been shown to improve or stabilize visual acuity in eyes with nAMD in many real-life studies [3,4], some patients present visual acuity loss despite retreatment or experience persistent exudative manifestations. When aflibercept became available, many authors reported their experience in switching from ranibizumab to aflibercept.…”

Resultate nach Rückumstellung von intravitrealem Aflibercept auf Ranibizumab bei persistierender Aktivität einer altersbedingten Makuladegeneration

“…Dagegen wird Bevacizumab (Avastin ® ) nur als Off-Label-Präparat verwendet. Zwar konnte für Ranibizumab in vielen Studien eine Stabilisierung oder Verbesserung der Sehschärfe bei gleichzeitiger Reduktion der sub-und intraretinalen Flüssigkeit nachgewiesen werden [7][8][9][10][11][12], jedoch wurden in diesen Studien auch immer Patienten beschrieben, bei denen ein Rückgang der Sehschärfe oder ein persistierendes Makulaödem zu beobachten war. Seit der Zulassung von Aflibercept war somit bei unbefriedigender Befundkonstellation nach der vorangegangenen Ranibizumab-Injektion eine Alternative zur Therapieumstellung vorhanden.…”